Screening Phytocompounds of Tinospora cordifolia to Find Potential Drug Targets for Cystic Fibrosis

Year : 2025 | Volume : 03 | Issue : 01 | Page : 16 24
    By

    Saumya Singh,

  1. Student, Department of Bioinformatics, BioNome, Bangalore, Karnataka, India

Abstract

This study aimed to evaluate the therapeutic potential of phytocompounds derived from Tinospora cordifolia in treating cystic fibrosis (CF), a genetic disorder caused by mutations in the CFTR gene that lead to severe respiratory and digestive complications. Phytocompounds were retrieved from the IMPPAT database and subjected to molecular docking simulations using PyRx to assess their binding affinity to the CFTR protein. The top-scoring compounds – sterol, magnoflorine, tembetarine, kaempferol, and tinosporinone – were identified based on their strong interaction with the target protein. To evaluate their suitability as drug candidates, ADMET (Absorption, Distribution, Metabolism, Excretion, and Toxicity) analysis was performed. Results revealed that all five compounds demonstrated favorable pharmacokinetic and pharmacodynamic properties, including high gastrointestinal absorption, good bioavailability, and low predicted toxicity. Additionally, the compounds satisfied essential drug-likeness criteria, highlighting their potential for therapeutic application. These findings underscore the promise of Tinospora cordifolia phytocompounds as a natural source for CF drug development. However, while the In silico approach provides a strong basis, further validation through in vitro and in vivo studies is necessary to confirm their biological activity and clinical relevance. This study highlights the role of bioinformatics in discovering plant-based treatments for genetic disorders like CF.

 

Keywords: Tinospora cordifolia, cystic fibrosis, CFTR, molecular docking, ADMET analysis, phytocompounds, drug-likeness

[This article belongs to International Journal of Genetic Modifications and Recombinations ]

How to cite this article:
Saumya Singh. Screening Phytocompounds of Tinospora cordifolia to Find Potential Drug Targets for Cystic Fibrosis. International Journal of Genetic Modifications and Recombinations. 2025; 03(01):16-24.
How to cite this URL:
Saumya Singh. Screening Phytocompounds of Tinospora cordifolia to Find Potential Drug Targets for Cystic Fibrosis. International Journal of Genetic Modifications and Recombinations. 2025; 03(01):16-24. Available from: https://journals.stmjournals.com/ijgmr/article=2025/view=197439


Browse Figures

References

1. Gupta A, Gupta P, Bajpai G. Tinospora cordifolia (Giloy): An insight on the multifarious pharmacological paradigms of a most promising medicinal ayurvedic herb. Heliyon. 2024 Feb 15.
2. Ahsan R, Mishra A, Badar B, Owais M, Mishra V. Therapeutic Application, phytoactives and pharmacology of Tinospora cordifolia: An evocative review. Chinese J Integrat Med. 2023 Jun;29(6):549–55.
3. Kumbhar ST, Mehta AB, Bote SS, Chaugule PA. Antiasthamatic Activity of Tinospora Cordifolia Leaves Extract on Ova Induced Airway Inflammation in Rats.
4. Murshid GM, Kundu SK, Sohrab MH, Mazid MA. Pharmacological overview of Tinospora cordifolia, an ethnologically important plant of Bangladesh. Pharmaco Pharma. 2022 Mar 25;13(3):93–106.
5. Arunachalam K, Yang X, San TT. Tinospora cordifolia (Willd. ) Miers: Protection mechanisms and strategies against oxidative stress-related diseases. J Ethnopharma. 2022 Jan 30;283:114540.
6. López-Valdez JA, Aguilar-Alonso LA, Gándara-Quezada V, Ruiz-Rico GE, Ávila-Soledad JM, Reyes AA, et al. Cystic fibrosis: current concepts. Boletín médico del Hospital Infantil de México. 2021 Dec;78(6):584–96.
7. Ghori SS, Fathima I, Qureshi SM, Tehseen F. Evaluation of antiasthmatic activity of Tinospora cordifolia root extract against ACH and citric acid induced asthmatic rats. Plant Archiv. 2020;20(2):4221–3.
8. Kapnadak SG, Dimango E, Hadjiliadis D, Hempstead SE, Tallarico E, Pilewski JM, et al. Cystic Fibrosis Foundation consensus guidelines for the care of individuals with advanced cystic fibrosis lung disease. J Cystic Fibros. 2020 May 1;19(3):344–54.
9. Wallis C. Diagnosis and presentation of cystic fibrosis. In: Kendig’s disorders of the respiratory tract in children. Elsevier. 2019 Jan 1. pp. 769–76.
10. Sharma P, Dwivedee BP, Bisht D, Dash AK, Kumar D. The chemical constituents and diverse pharmacological importance of Tinospora cordifolia. Heliyon. 2019 Sep 1;5(9).
11. Turcios NL. Cystic fibrosis lung disease: an overview. Respirat Care. 2020 Feb 1;65(2):233-51.
12. Jabiullah SI, Battineni JK, Bakshi V, Boggula N. Tinospora cordifolia: A medicinal plant: A review. Growth. 2018;9:11.
13. Kumar R. A Randomized Study of Effect of Tinospora Cordifolia in Chronic Bronchitis Patients. IOSR J. Dental Med Sci. 2018;17(7):5–10.
14. Mohan V, Koul A. Anticancer potential of Tinospora cordifolia and arabinogalactan against benzo (a) pyrene induced pulmonary tumorigenesis: a study in relevance to various biomarkers. J Herbmed Pharmaco. 2018 Oct 6;7(4):225–35.
15. Corriveau S, Sykes J, Stephenson AL. Cystic fibrosis survival: the changing epidemiology. Current Opinon Pulm Medi. 2018 Nov 1;24(6):574–8.
16. Sinha K, Mishra NP, Singh J, Khanuja SP. Tinospora cordifolia (Guduchi), a reservoir plant for therapeutic applications: A Review.
17. Sharma R, Amin H, Prajapati PK. Antidiabetic claims of Tinospora cordifolia (Willd) Miers: critical appraisal and role in therapy. Asian Pacif J Tropicl Biomed. 2015 Jan 1;5(1):68–78.
18. Spelman K. Traditional and clinical use of Tinospora cordifolia, Guduchi. AustralnJ Med Herbalism. 2001 Jan;13(2).
19. Chaudhary A, Das R, Mehta K, Mehta DK. Indian herb Tinospora cordifolia and Tinospora species: Phytochemical and therapeutic application. Heliyon. 2024 May 16.
20. Reddy NM, Reddy RN. Tinospora cordifolia chemical constituents and medicinal properties: a review. Sch Acad J Pharm. 2015 Nov;4(8):364–9.
21. Nyarko RO, Kumar R, Sharma S, Chourasia A, Roy A, Saha P. Antibacterial Activity of Herbal Plant-Tinospora Cordifolia and Catharnthus Roseus.
22. Sharma A, Bajaj P, Bhandari A, Kaur G. From ayurvedic folk medicine to preclinical neurotherapeutic role of a miraculous herb, Tinospora cordifolia. Neurochem Intl. 2020 Dec 1;141:104891.
23. Choudhary N, Siddiqui MB, Azmat S, Khatoon S. Tinospora cordifolia: ethnobotany, phytopharmacology and phytochemistry aspects. Intl J Pharmaceu Sci Res. 2013 Mar 1;4(3):891.
24. Upadhyay AK, Kumar K, Kumar A, Mishra HS. Tinospora cordifolia (Willd. ) Hook. f. and Thoms. (Guduchi)–validation of the Ayurvedic pharmacology through experimental and clinical studies. Intl J Ayurvd Res. 2010 Apr;1(2):112.
25. Allen L, Allen L, Carr SB, Davies G, Downey D, Egan M, et al. Future therapies for cystic fibrosis. Natur Commun. 2023 Feb 8;14(1):693.
26. Bear CE. A therapy for most with cystic fibrosis. Cell. 2020 Jan 23;180(2):211.
27. Kayani K, Mohammed R, Mohiaddin H. Cystic fibrosis-related diabetes. Frontiers Endocrinol. 2018 Feb 20;9:20.
28. Bergeron C, Cantin AM. Cystic fibrosis: pathophysiology of lung disease. In: Seminars in respiratory and critical care medicine. Thieme Medical Publishers. 2019 Dec;40(06):715–26.
29. McBennett KA, Davis PB, Konstan MW. Increasing life expectancy in cystic fibrosis: Advances and challenges. Pediatr Pulmo. 2022 Feb;57:S5–12.

Regular Issue Subscription Review Article
Volume 03
Issue 01
Received 27/12/2024
Accepted 06/02/2025
Published 08/02/2025
Publication Time 43 Days
332

Login


My IP

PlumX Metrics